Back
ARS Pharmaceuticals, Inc. 10K Form
Sell
47
SPRY
ARS Pharmaceuticals, Inc.
Last Price:
$9.98
Seasonality Move:
7.95%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive SPRY News And Ratings
See the #1 stock for the next 7 days that we like better than SPRY
SPRY Financial Statistics
Sales & Book Value
| Annual Sales: | $89.1M |
|---|---|
| Cash Flow: | $-47.2M |
| Price / Cash Flow: | 96.16 |
| Annual Sales: | $1.49 |
| Price / Book: | 6.67 |
Profitability
| EPS (TTM): | -0.81030 |
|---|---|
| Net Income (TTM): | $-80M |
| Gross Margin: | $88M |
| Return on Equity: | -38.98% |
| Return on Assets: | -25.29% |
ARS Pharmaceuticals, Inc. Earnings Forecast
Key ARS Pharmaceuticals, Inc. Financial Ratios
-
The Gross Profit Margin over the past 7 years for SPRY is 98.67%.
-
The Selling, General & Administrative Expenses for SPRY have been equal to 80.40% of Gross Profit Margin.
-
The Research & Development expenses have been 21.96% of Revenue.
-
The Interest Expense is 0.00% of Operating Income.
-
The Net Earning history of SPRY is 8.97% of Total Revenues.
-
Per Share Earnings over the last 7 years have been positive in 3 years.
ARS Pharmaceuticals, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | SPRY |
| Website: | ars-pharma.com |
Debt
| Debt-to-Equity Ratio: | 0.66 |
|---|---|
| Current Ratio: | 6.66 |
| Quick Ratio: | 6.38 |
Price-to-Earnings
| Trailing P/E Ratio: | 127.66 |
|---|---|
| Forward P/E Ratio: | 183.83 |
SPRY Technical Analysis vs Fundamental Analysis
Sell
47
ARS Pharmaceuticals, Inc. (SPRY)
is a Sell
Is ARS Pharmaceuticals, Inc. a Buy or a Sell?
-
ARS Pharmaceuticals, Inc. stock is rated a SellThe current ARS Pharmaceuticals, Inc. [SPRY] share price is $9.97. The Score for SPRY is 47, which is 6% below its historic median score of 50, and infers higher risk than normal.